



Wellmark Blue Cross and Blue Shield is an independent licensee of the Blue Cross and Blue Shield Association.

Mavyret (glecaprevir and pibrentasvir)

NOTICE

This policy contains information which is clinical in nature. The policy is not medical advice. The information in this policy is used by Wellmark to make determinations whether medical treatment is covered under the terms of a Wellmark member's health benefit plan. Physicians and other health care providers are responsible for medical advice and treatment. If you have specific health care needs, you should consult an appropriate health care professional. If you would like to request an accessible version of this document, please contact customer service at 800-524-9242.

BENEFIT APPLICATION

Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This medical policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

DESCRIPTION

The intent of the Mavyret drug policy is to ensure clinically suitable, cost-effective therapy for members based on product labeling, clinical guidelines and clinical studies while maintaining optimal therapeutic results. Due to the constant changing treatment landscape of Hepatitis C with newly published data, developments, and new regimens available, the indications recommended in The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) Hepatitis C guidelines are considered a covered benefits provided that all the approval criteria are met, the member has no exclusions to the prescribed therapy, and guidelines reflect most recent evidence available.

POLICY

Required Documentation

The following information is necessary to initiate the prior authorization review:

- Presence of viral load (HCV RNA) in the serum prior to treatment with the requested regimen
- Genotype and subtype (if applicable)
- Baseline or current viral load
- Laboratory testing for resistance-associated variants (if applicable)
- METAVIR fibrosis score (if applicable)
- Liver transplantation status
- Treatment plan including treatment regimen and duration

- Prior treatment regimen(s) and response
- Prescriber specialty

Exclusions

Coverage will not be provided for members with decompensated cirrhosis/moderate or severe hepatic impairment (Child Turcotte Pugh Class B or C)

Note: When the requested drug is being used in a combination therapy regimen, exclusions to the other antiviral drugs also apply.

Criteria for Initial Approval

A. Chronic hepatitis C virus infection

1. Genotype 1 infection

- Authorization of up to 8 weeks total may be granted for treatment-naïve members without cirrhosis or with compensated cirrhosis.
- Authorization of up to 12 weeks total may be granted for treatment naïve members with compensated cirrhosis and HIV coinfection.
- Authorization of up to 16 weeks total may be granted for members without cirrhosis or with compensated cirrhosis who failed prior treatment with an NS5A inhibitor (excluding glecaprevir/pibrentasvir) and who have not received an NS3/4A protease inhibitor.
- Authorization of up to 12 weeks total may be granted for members without cirrhosis or with compensated cirrhosis who failed prior treatment with an NS3/4A protease inhibitor (e.g., simeprevir, boceprevir or telaprevir in combination with peginterferon and ribavirin, simeprevir with sofosbuvir) and who have not received an NS5A inhibitor.
- Authorization of up to 8 weeks total may be granted for members without cirrhosis who failed prior treatment with peginterferon-alfa (PEG-IFN) and ribavirin (RBV) and who have not received an NS3/4A protease inhibitor or NS5A inhibitor.
- Authorization of up to 12 weeks total may be granted for members with compensated cirrhosis who failed prior treatment with PEG-IFN and RBV and who have not received an NS3/4A protease inhibitor or NS5A inhibitor.
- Authorization of up to 12 weeks total may be granted for members without cirrhosis or with compensated cirrhosis who failed prior treatment with a sofosbuvir (Sovaldi)-containing regimen (e.g., sofosbuvir and ribavirin with or without PEG-IFN) and who have not received an NS3/4A protease inhibitor or NS5A inhibitor.

2. Genotype 2 infection

- Authorization of up to 8 weeks total may be granted for treatment-naïve members without cirrhosis or with compensated cirrhosis.
- Authorization of up to 12 weeks total may be granted for treatment naïve members with compensated cirrhosis and HIV coinfection.
- Authorization of up to 8 weeks total may be granted for members without cirrhosis who failed prior treatment with PEG-IFN and RBV and who have not received an NS3/4A protease inhibitor or NS5A inhibitor.
- Authorization of up to 12 weeks total may be granted for members with compensated cirrhosis who failed prior treatment with PEG-IFN and RBV and who have not received an NS3/4A protease inhibitor or NS5A inhibitor.
- Authorization of up to 12 weeks total may be granted for members without cirrhosis or with compensated cirrhosis who failed prior treatment with sofosbuvir (Sovaldi) and ribavirin with or without PEG-IFN and who have not received an NS3/4A protease inhibitor or NS5A inhibitor.

3. Genotype 3 infection

- a) Authorization of up to 8 weeks total may be granted for treatment-naive members without cirrhosis or with compensated cirrhosis.
- b) Authorization of up to 12 weeks total may be granted for treatment naïve members with compensated cirrhosis and HIV coinfection.
- c) Authorization of up to 16 weeks total may be granted for members without cirrhosis or with compensated cirrhosis who failed prior treatment with PEG-IFN and RBV and who have not received an NS3/4A protease inhibitor or NS5A inhibitor.

4. Genotype 4, 5, or 6 infection

- a) Authorization of up to 8 weeks total may be granted for treatment-naive members without cirrhosis or with compensated cirrhosis.
- b) Authorization of up to 12 weeks total may be granted for treatment naïve members with compensated cirrhosis and HIV coinfection.
- c) Authorization of up to 8 weeks total may be granted for members without cirrhosis who failed prior treatment with PEG-IFN and RBV and who have not received an NS3/4A protease inhibitor or NS5A inhibitor.
- d) Authorization of up to 12 weeks total may be granted for members with compensated cirrhosis who failed prior treatment with PEG-IFN and RBV and who have not received an NS3/4A protease inhibitor or NS5A inhibitor.

5. Recurrent HCV infection post liver transplantation

- a) Authorization of up to 12 weeks total may be granted for members without cirrhosis or with compensated cirrhosis who develop recurrent HCV genotype 1, 2, 3, 4, 5 or 6 infection post liver transplantation.
- b) Authorization of up to 16 weeks total may be granted for members with recurrent HCV genotype 1 infection post liver transplantation without cirrhosis or with compensated cirrhosis who failed prior treatment with an NS5A inhibitor (excluding glecaprevir/pibrentasvir) and who have not received an NS3/4A protease inhibitor.
- c) Authorization of up to 16 weeks total may be granted for members with recurrent HCV genotype 3 infection post liver transplantation without cirrhosis or with compensated cirrhosis who failed prior treatment with PEG-IFN and RBV and who have not received an NS3/4A protease inhibitor or NS5A inhibitor.
- d) Authorization of up to 16 weeks total may be granted for members with HCV genotype 3 infection post liver transplantation without cirrhosis or with compensated cirrhosis who failed prior treatment with sofosbuvir (Sovaldi) and RBV with or without PEG-IFN and who have not received an NS3/4A protease inhibitor or NS5A inhibitor.

6. Kidney transplant recipients

- a) Authorization of up to 12 weeks total may be granted for members without cirrhosis or with compensated cirrhosis who have HCV genotype 1, 2, 3, 4, 5 or 6 infection.
- b) Authorization of up to 16 weeks total may be granted for members with HCV genotype 1 infection without cirrhosis or with compensated cirrhosis who failed prior treatment with an NS5A inhibitor (excluding glecaprevir/pibrentasvir) and who have not received an NS3/4A protease inhibitor.
- c) Authorization of up to 16 weeks total may be granted for members with recurrent HCV genotype 3 infection without cirrhosis or with compensated cirrhosis who failed prior treatment with PEG-IFN and RBV and who have not received an NS3/4A protease inhibitor or NS5A inhibitor.
- d) Authorization of up to 16 weeks total may be granted for members with HCV genotype 3 infection without cirrhosis or with compensated cirrhosis who failed prior treatment with

sofosbuvir (Sovaldi) and RBV with or without PEG-IFN and who have not received an NS3/4A protease inhibitor or NS5A inhibitor

7. Organ recipient from HCV-RNA-positive donor

Authorization of up to 12 weeks total may be granted for members who have received an organ transplanted from an HCV-RNA-positive donor.

B. Hepatitis C virus infection, in combination with Sovaldi and ribavirin

Genotype 1,2,3,4,5, or 6 infection

- a) Authorization of up to 16 weeks total may be granted for members with HCV genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis who failed initial treatment with glecaprevir/pibrentasvir (Mavyret).
- b) Authorization of up to 16 weeks total may be granted for members with HCV genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis who failed initial treatment with sofosbuvir/velpatasvir/voxilaprevir (Vosevi).

C. HCV and HIV Coinfection

Authorization may be granted for members with HCV and HIV coinfection when the criteria for approval of the requested regimen in Section A above are met.

Continuation of Therapy

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

Prior Approval is required.

Dosing and Administration

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Dosing Limits

- The following dosing limits apply: 3 tablets/day. Lifetime Maximum 336 tablets (672 if meets criteria B a) above).

Dispensing Limits

- A 28-day supply dispense limit applies to all targeted hepatitis C agents in order to better manage the therapy regimen.

PROCEDURES AND BILLING CODES

To report provider services, use appropriate CPT* codes, Alpha Numeric (HCPCS level 2) codes, Revenue codes, and/or ICD diagnostic codes.

REFERENCES

- Mavyret [package insert]. North Chicago, IL: AbbVie Inc.; April 2020.
- AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. <http://www.hcvguidelines.org>. Last changes made on August 27, 2020. Accessed September 18, 2020.

*Some content reprinted from CVSHealth

POLICY HISTORY

Policy #: 05.02.30

Original Effective Date: January 5, 2018

Reviewed: October 2020

Revised: October 2020

Current Effective Date: January 22, 2021